Background Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefi t from statin therapy.
Introduction
The risk of developing coronary heart disease depends on several factors that are related both to lifestyle and genetics. Heritable factors account for as much as 30-60% of the variation in risk, 1, 2 and large-scale studies have identifi ed genetic variants associated with coronary heart disease at stringent levels of statistical signifi cance. 3, 4 Previous studies have shown that an assessment of genetic risk burden based on several loci can identify individuals at increased risk for incident coronary heart disease in population-based epidemiological cohorts. [5] [6] [7] [8] [9] [10] [11] [12] Additionally, whereas some individual variants have been assessed in isolated studies for an association with recurrent events, an independent association between a multi-locus genetic risk score and recurrent coronary heart disease events has not been clearly shown. [13] [14] [15] [16] The clinical benefi t from treatments that reduce the likelihood of coronary heart disease events might vary by the degree of risk at baseline. As such, in addition to identifying risk, a genetic risk score consisting of fully studied coronary heart disease risk single-nucleotide polymorphisms (SNPs) might also characterise individuals who will receive the greatest clinical benefi t from statin therapy. Such a fi nding would be of particular interest in the primary prevention setting. Therefore, our study had two main goals: fi rst, to test if a multi-locus genetic risk score based on a combination of 27 loci might predict not only incident coronary heart disease in an epidemiological cohort but also incident or recurrent coronary heart disease events in a clinical trial setting; and second, to assess whether or not the clinical benefi t of statin therapy varies by genetic risk score in four randomised controlled trials of statin therapy.
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Methods

Primary prevention populations
The baseline characteristics of the participants of each study are listed in appendix p 4. In brief, the Malmo Diet and Cancer Study (MDCS) 17 is a communitybased prospective epidemiological cohort of middle-aged (45-64 years old) individuals from southern Sweden. Genetic samples were available from 27 817 people without documented coronary heart disease at baseline. JUPITER 18 was a primary prevention trial that tested rosuvastatin 20 mg daily versus placebo in 17 802 individuals with LDL cholesterol level lower than 3·37 mmol/L, high-sensitivity C-reactive protein of 2 mg/L or higher, and no known cardiovascular disease. Genetic samples were available in 8749 individuals for this analysis. Another primary prevention trial, ASCOT, 19 tested the clinical benefi t of diff erent classes of antihypertensive therapy in 19 342 high-risk individuals without documented coronary heart disease. The lipidlowering group (ASCOT-LLA) randomly assigned individuals from the main trial with a total cholesterol level of up to 6·5 mmol/L to either atorvastatin 10 mg daily or placebo. In total, 4219 individuals from ASCOT-LLA were included in the treatment-related analyses. Additionally, 2759 participants from the blood pressurelowering group of ASCOT who were not receiving a statin drug were assessed in the non-treatment-related analyses.
Secondary prevention populations
CARE
20 was a secondary prevention trial that investigated the clinical benefi t of pravastatin 40 mg daily versus placebo in 4159 individuals with previous myocardial infarction who had total cholesterol level of up to 6·2 mmol/L and LDL cholesterol level between 3·0 and 4·5 mmol/L. Genetic samples were available for 2878 individuals in this study. Another secondary prevention trial, PROVE IT-TIMI 22, investigated the clinical benefi t of moderate statin therapy (pravastatin 40 mg daily) versus intensive statin therapy (atorvastatin 80 mg daily) in 4162 patients after an acute coronary syndrome who had total cholesterol level of up to 6·2 mmol/L. 21 A genetic substudy included 1999 individuals.
Genetic risk score
A genetic risk score was derived on the basis of 27 SNPs that were signifi cantly associated with coronary heart disease at a genome-wide level in previous analyses (appendix p 2).
22 Table 1 shows the loci, lead SNPs, published eff ect sizes, risk alleles, and risk allele frequency, with the specifi cs for each study provided in appendix p 5. Each individual participant received a score equal to the sum of the number of risk alleles for each SNP weighted by the log of the odds ratio reported with the SNP in the original report (appendix pp [13] [14] [15] [16] .
Outcomes
The outcome of interest was coronary heart disease, in view of the fact that the SNPs were originally reported to be associated with coronary events. We attempted to harmonise the defi nitions across studies based on the available endpoints. In JUPITER, ASCOT, and PROVE IT-TIMI 22, coronary heart disease was defi ned as a composite of coronary heart death, myocardial infarction, or unstable angina. In MDCS, coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention, and in CARE, coronary heart disease was coronary heart death or myocardial infarction.
Statistical analysis
We used Cox proportional hazard models to assess the risk of coronary heart disease for each quintile of genetic risk, in which we used the fi rst quintile as the reference group; additionally, the risk for categories ( 
Risk allele frequency data are from the Malmo Diet and Cancer Study. 17 SNP=single-nucleotide polymorphism. OR=odds ratio. were done on participants in MDCS, and in the placebo or lower-intensity statin treatment groups of the applicable trials. The models were adjusted for age, sex, diabetes status, smoking, race (if applicable), family history of coronary heart disease, HDL chol esterol, LDL cholesterol, and hypertension. In a meta-analysis, the estimates were combined from each study by use of a random-eff ects model to account for possible diff erences in study populations. We assessed heterogeneity across studies and types of studies, and analyses were stratifi ed on the basis of the primary and secondary prevention populations. The treatment-specifi c analyses were done in the JUPITER, ASCOT, CARE, and PROVE IT-TIMI 22 trials. The eff ect of statin versus placebo (or high-intensity versus moderate-intensity statin in the case of PROVE IT-TIMI 22) was assessed, and the number of events and event rates in the statin and placebo groups were analysed on the basis of the genetic risk score quintiles and aforementioned categories. Hazard ratios and 95% CIs were generated, and absolute risk reductions were calculated. For the primary prevention trials (JUPITER and ASCOT), we extrapolated 10-year event rates and calculated the numbers needed to treat for each study.
We combined the relative risk ratios for the benefi t of statin therapy within each genetic risk score category across the trials using meta-analytical techniques, with separate analyses for the primary and secondary prevention populations. We assessed the resulting meta-analysis risk ratios across the genetic risk score categories with meta-regression. In terms of absolute risk reductions with statins, within each trial and within each genetic risk score category, the absolute risk diff erence for statin versus placebo and corresponding standard errors and 95% CIs were generated. Notably, the fact that the trials had populations with diff erent absolute event rates (owing to varying degrees of cardiovascular risk and diff erent durations of follow-up) precluded us from obtaining a clinically interpretable result by merely combining the raw absolute risk diff erences across the four trials. Therefore, to normalise across the trials, we applied a scaling factor to the data (see appendix p 3 for further details). Then, within the data from each trial, meta-regression was done across the genetic risk score categories to establish how the relative magnitude of absolute risk reduction with statin therapy varied by genetic risk score category. We then undertook meta-analysis in which we combined the regression coeffi cients from the four trials, again stratifi ed by primary and secondary prevention populations.
Role of the funding source
For this analysis, the funders of the individual clinical trials had no role in the analysis or interpretation of the data, or writing of the report. Investigators associated with each study had access to the data, and JLM, NOS, SK, and MSS were responsible for the fi nal decision to submit for publication.
Results
Higher genetic risk scores were associated with a raised risk of coronary heart disease, independent of estab lished clinical predictors. 
Secondary prevention populations
Data are adjusted hazard ratios (95% CI), unless otherwise indicated. These analyses were done in participants in the Malmo Diet and Cancer Study, and in those in the placebo groups (in JUPITER, ASCOT, and CARE) or the lower-intensity statin treatment group (in PROVE IT-TIMI 22). was evident in the studies (table 2) . When the data from the primary prevention cohorts were combined, the multivariable-adjusted hazard ratios (HRs) for incident coronary heart disease compared with the low genetic risk category were 1·31 (95% CI 1·19-1·45, p<0·0001) for the intermediate genetic risk category and 1·72 (1·53-1·92, p<0·0001) for the high genetic risk category (table 2) . Similarly, the multivariableadjusted HRs for recurrent coronary heart disease in the secondary prevention cohorts were 1·65 (1·19-2·30, p=0·0030) for the intermediate genetic risk category and 1·81 (1·22-2·67, p=0·0029) for the high genetic risk category (table 2) . Overall, the multivariableadjusted HRs were 1·34 (95% CI 1·22-1·47, p<0·0001) and 1·72 (1·55-1·92, p<0·0001), respectively (fi gure 1). Data for individual quintiles 1-5 were similar (see appendix pp 6-7). Baseline LDL cholesterol and HDL cholesterol levels were similar across genetic risk score categories within each trial, as were the absolute and percentage changes with statin therapy (appendix pp 8-10). Analyses were done to investigate the clinical benefi t of statin therapy across genetic risk score. The benefi t of statin versus placebo in the primary and secondary prevention trials with a total of 806 events is presented across genetic risk score categories in table 3 and genetic risk score quintiles in appendix pp 11-12. The relative risk reductions were 34% in low, 32% in intermediate, and 50% in high genetic risk score categories in the primary prevention trials, and 3% in low, 28% in intermediate, and 47% in high genetic risk score categories in the secondary prevention trials. When the data were combined, the gradient of relative risk reductions with statin therapy across low, intermediate, and high genetic risk score categories were 13%, 29%, and 48%, respectively (p value for trend=0·0277, fi gure 2).
Similarly, in terms of the absolute risk reductions, a graded increase in the benefi t of statin therapy across the genetic risk score categories (from low risk to high risk) was evident in both the primary prevention trials (JUPITER and ASCOT) and the secondary prevention trials (CARE and PROVE IT-TIMI 22; table 3, fi gure 3). Correspondingly, the number needed to treat to reduce coronary heart disease events with statin therapy diff ered depending on genetic risk score. With a focus on the primary prevention trials, in JUPITER, the number needed to treat to prevent one coronary event in 10 years was 66 for those individuals with a low genetic risk score, 42 for those with an intermediate score, and 25 for those with a high score. In ASCOT, the number needed to treat to prevent one coronary heart disease event in 10 years was 57, 47, and 20, respectively, across the three genetic risk score categories.
Calculation of the diff erence in absolute risk reduction in each trial as a function of genetic risk score category and combination of the data from the trials showed a consistent and signifi cant gradient, with greater absolute risk reductions recorded in those individuals in higher genetic risk score categories (p=0·0101, appendix p 17 HR=hazard ratio. ARR=absolute risk reduction. *In PROVE IT-TIMI 22, the control group is moderate-intensity statin therapy (pravastatin 40 mg) and the statin group is high-intensity statin therapy (atorvastatin 80 mg). 
Discussion
Large-scale genetic association studies have identifi ed several genetic variants that are individually associated with the risk of coronary heart disease. When combined into a 27-variant risk score, our multivariable-adjusted analyses showed that these variants could identify people at increased risk of coronary heart disease events, including incident coronary heart disease in primary prevention populations and recurrent coronary heart disease events in secondary prevention populations. Furthermore, when compared with people at low genetic risk, those with the highest genetic risk scores derived greater relative risk reduction and absolute risk reduction with statin therapy. Notably, in the primary prevention trials we found a roughly threefold diff erence between the low and high genetic risk score groups in the number needed to treat to prevent one coronary heart disease event.
Clinical, biochemical, and imaging parameters have been used to stratify cardiovascular risk and potentially to tailor therapy. 23 Our present analysis suggests that genetics might also have such a role. Previous data for genetic variants predicting recurrent coronary heart disease events independent of traditional risk factors are inconclusive, [13] [14] [15] [16] which is perhaps a result of varying defi nitions of prevalent coronary heart disease (eg, angina vs documented myocardial infarction) and inclusion of less specifi c outcomes (eg, non-cardiovascular death) in a composite endpoint. In terms of treatment options, the decision to prescribe any drug depends on weighing up of several factors, including effi cacy, safety, and cost. In the case of statins, substantial relative risk reductions in major cardiovascular outcomes have been shown across the range of primary and secondary prevention. 24 Absolute risk reductions can depend on the risk profi le of the population, but even in individuals at low risk of coronary heart disease, statins off er clinical benefi t. 25 Nonetheless, debate continues about the use of statins in people at lower risk of coronary heart disease events, especially in primary prevention populations, 26 which is driven by concerns about safety and cost-eff ectiveness in an extremely broad population. For that reason, an understanding of the absolute risk reductions achieved with statin therapy in diff erent subgroups could be useful in some circumstances. Moreover, lifetime risk of coronary heart disease is now receiving increased attention, and information about genetic risk could be obtained early in life. 27 As such, discussions have taken place about whether or not statin therapy could be considered at an earlier stage in people who do not currently meet practice guidelines, but who might still be at raised risk of coronary heart events. To defi ne the best approach to maximise the benefi t of statin therapy in such a population is a complex challenge that needs further study. A genetic risk score off ers a unique perspective into future risk and could help in the selection Hazard ratios for coronary heart disease with statin therapy across genetic risk score categories The boxes indicate the point estimates, and the size of each box represents the weight of a trial's data within that subgroup. The horizontal lines are the 95% CIs. The diamonds provide summary data. In PROVE IT-TIMI 22, the control group is moderate-intensity statin therapy (pravastatin 40 mg) and the statin group is high-intensity statin therapy (atorvastatin 80 mg).
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Figure 3: Absolute risk reductions of coronary heart disease events with statin therapy across genetic risk score categories In PROVE IT-TIMI 22, the control group is moderate-intensity statin therapy (pravastatin 40 mg) and the statin group is high-intensity statin therapy (a torvastatin 80 mg). Previous analyses have assessed genetics and coronary heart disease events in the setting of statin therapy. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] However, such approaches have been limited by either examination of only one SNP, the use of SNPs whose association with coronary heart disease has not been well validated, not testing the SNP in a randomised trial of statin therapy, or not consistently validating any observed interactions. By contrast, our present analysis used a multi-locus genetic risk score comprised of well-validated coronary heart disease-risk SNPs and tested the score in four randomised controlled trials of statin therapy.
Our analyses have some potential limitations. First, data from several studies were used in this analysis, and each study has its own entry criteria, treatment allocation, and duration of follow-up. As such, the hazards associated with the genetic risk categories diff ered somewhat, with the genetic-based risk in JUPITER apparently the lowest, which was possibly related to the patient population or the lower event rates than the other studies. However, the fact that we had access to data from a large community cohort study (MDCS), in addition to primary and secondary prevention clinical trials, allowed us to test the generalisability of the genetic risk score across various populations. Second, the numbers needed to treat were calculated by extrapolation of the eff ect of statin therapy during a 10-year period, and the treatment eff ect could vary over time. Nonetheless, studies of statin therapy suggest quite a linear long-term association with coronary event reduction. 41 Third, these analyses were done within completed clinical trials, and the genetic risk score was not used specifi cally as an enrolment criterion. Dedicated clinical trials using a genetic risk score to triage statin therapy would add further to the knowledge base. Fourth, although we focused on the ability of genetics to off er insight into the risk of coronary heart disease and benefi t of statin therapy, optimum tailoring of therapy might need a combination of several factors. Fifth, the present analysis focuses on genetic variants that were associated with the risk of coronary heart disease. Other variants have been described that are associated with LDL cholesterol levels. However, these variants mainly aff ect baseline LDL cholesterol, which is already routinely measured. Moreover, as previous studies show, they have little eff ect on the change in LDL cholesterol with statins or the clinical response to statin therapy. 42, 43 Therefore, our present analyses do not explore such variants unless they previously showed an association with coronary heart disease. Nonetheless, such a line of inquiry might also be informative. Finally, the gradient of relative risk reduction across genetic risk score categories in the present study was unexpected. Data from other studies suggest that patients with more versus less coronary heart disease risk SNPs have more extensive atherosclerosis, 8 and thus, patients with a higher burden of these SNPs might well experience a greater benefi t with statin therapy because more plaques are present that can be stabilised. However, this idea merits further study to elucidate the underlying mechanisms.
In conclusion, our study showed that a genetic risk score identifi ed individuals at increased risk of coronary heart disease across primary and secondary prevention populations. Furthermore, people with high genetic risk scores had the largest relative and absolute risk reductions with statin therapy. In situations in which optimisation of the number needed to treat is relevant, such as in the primary prevention setting, approaches that involve genetics could prove useful.
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Panel: Research in context
Systematic review
We searched PubMed for original research relevant to this analysis published in English within the past 30 years. We used the following combination of keywords: "genetic", "risk score", and "coronary disease", and identifi ed studies that describe the association of genetic variants and the risk of coronary heart disease, including several analyses examining the prognostic signifi cance of several genetic variants, although these studies were largely confi ned to epidemiological cohorts and prediction of fi rst manifestation of coronary heart disease. We also searched for "genetic", "risk score", "coronary disease", and "statins" without identifying studies that directly tested this specifi c concept. Therefore, in the present study we aimed to test whether or not a multi-locus genetic risk score predicts not only incident coronary heart disease in an epidemiological cohort but also recurrent coronary heart disease events in a clinical trial setting; and to assess whether or not the clinical benefi t of statin therapy varies by genetic risk score.
Interpretation
A genetic risk score was derived based on 27 single-nucleotide polymorphisms that have been signifi cantly associated with coronary heart disease at a genome-wide level in previous analyses. First, in an epidemiological cohort, people with a high genetic risk score were shown to have an increased risk of coronary heart disease, even after adjustment for established clinical predictors. We then assessed the association between the genetic risk score and coronary heart disease in primary and secondary prevention trials of statin therapy, and validated a gradient of risk for incident and recurrent coronary heart disease. In terms of the benefi t of statin therapy, we tested the genetic risk score in four clinical trials and identifi ed a signifi cant gradient of increasing relative risk reduction across the low, intermediate, and high genetic risk categories. Similarly, in each trial, greater absolute risk reductions were recorded in those individuals in higher genetic risk categories, resulting in a roughly threefold decrease in the number needed to treat in the primary prevention trials. Therefore, genetics could help in the selection of populations for clinical trials that, so enriched, would be better positioned to test the clinical benefi t of early initiation of statin therapy. Moreover, in situations in which optimisation of the number needed to treat is relevant, genetics could provide useful information.
